Microbubbles (MBs) are used in clinical practice as vascular ultrasound contrast agents, and are gaining popularity as a platform supporting multimodal imaging and targeted therapy, facilitating drug delivery under ultrasound exposure. Here, we report on the in vivo biological impact of newly discovered MBs with promising features as a multimodal theranostic device. The shell of the air-filled MBs is made of the poly(vinyl alcohol) (PVA), a well-established, FDA-approved polymer. Nevertheless, as size, shape and dispersity can significantly impact the 
Introduction
Ultrasound contrast agents (UCAs) in the form of microbubbles (MBs) are used clinically to increase the sensitivity and specificity of diagnostic ultrasonography. MBs are gas-filled voids with a diameter ranging from 1 to 8 mm, stabilised by an elastic shell (2e500 nm) composed of lipids, polymers or both (i.e. hybrid MBs) [1, 2, 3] . Owing to their ability to resonate when exposed to an ultrasound (US) field, they improve the scattering of the US wave thereby acting as "echo-enhancers". The reflection of a strong US signal depends on several parameters such as bubble size, concentration, gas pressure, and surface tension [4, 5] .
Over the years, the biomedical research has addressed to the implementation of UCAs in order to upgrade diagnostic agents turning them into theranostic devices.
In this perspective, MBs made of poly(vinyl alcohol) (PVA) have generated substantial interest for their promising potentialities in terms of improved stability and facile surface functionalisation for multimodal and targeting purposes. Therefore, understanding the fate of PVA MBs once injected into the blood circulation is of crucial importance in order to bring PVA MBs one step forward to clinical use.
PVA MBs are US-active [6, 7] , 3-mm sized particles made of a highly hydrated polymer shell of 200 nm thickness [8] . Their formation occurs during the foaming of oxidised telechelic PVA in an aqueous medium. At the water/air interface the air contained in the foam remains entrapped in the crosslinked PVA network forming the gas core of the MBs [9] .
The advantages of the PVA MBs lie in the shell as they show an excellent stability and versatility when compared to lipid shelled MBs. In vitro the cross-linked shell of PVA MBs has a remarkable shelf life of several months [9] . Marketed lipid Sonovue
MBs show an elimination half-life in the bloodstream of approximately 6 minutes and often more than one injection is required during an ultrasound investigation [10] . An increased stability is desirable especially in view of next generation UCAs for targeted molecular imaging. One of the problems of the targeting is that the number of adhering MBs is small in comparison to those in circulation, which generates a high background signal that can impair the detection of the target [11] . Waiting for the clearance of free MBs by the reticuloendothelial system is a possibility to overcome this problem but to this aim prolonged stability of microbubbles is required [12, 13] . On the other hand an excess of stability is not desirable as the key issues for injectable devices are the biodegradation and the bioelimination. Studies on the enzymatic degradation of PVA by different bacterial strains have been reported [14, 15, 16] while in animals the biodegradability and/or elimination of PVA is still under debate, despite the encouraging results of Kaneo et al. [17] concerning intravenously (IV) injected PVA.
The chemical versatility of PVA MBs depends on the hydroxyl and aldehyde moieties (masked at physiological pH as hemiacetals) [9] , which can be exploited for the tethering of active molecules thereby promoting targeted drug delivery [18, 19, 20, 21] . Moreover, the opportunity to conjugate dyes and magnetic nanoparticles on the shell fulfils the requirements of the diagnostic research which yearn for the availability of one injectable device that can permit multimodal imaging: US þ Fluorescence þ Magnetic Resonance Imaging (MRI). We have already demonstrated that superparamagnetic iron oxide nanoparticles successfully implement the modalities of the PVA MBs, enabling the activity of the MBs for MRI [22] . Among fluorescent probes, Near Infrared (NIR) fluorophores are gaining attention due to the following advantages: (i) tissues irradiated with NIR wavelengths present low absorption and low scattering, allowing images to be acquired with minimal tissue autofluorescence; (ii) NIR wavelengths can penetrate deeper into the skin going beyond the limit of 1e2 mm depth of the fluorescence imaging in the visible field [23, 24] . The somodified PVA MBs become a platform which combines the dual function of the real-time multimodal imaging and the in situ treatment of diseases such as tumours, decreasing the side effects linked to systemic tumour chemotherapies [25] .
Despite the lack of information regarding the in vivo safety of PVA MBs, a lot is known about the polymer. It is an FDA-approved biocompatible, non-toxic, inert synthetic polymer which already has several in vivo applications as a material for contact lenses, eye wetting drops and in implantable devices such as catheters, vascular embolic agents, tissue adhesion barriers and for cartilage replacements and nerve guide [26] . Moreover, it is often used alone or as part of copolymers for biomedical applications [27, 28, 29, 30, 31, 32] . Other synthetic polymers such as poly(lactide-co-glycolide) (PLGA) [33] , poly(DL-lactide) (PLA), polyalkylcyanoacrylate, and polycaprolactone (PCL) polymers [34] are commonly used as starting material for the synthesis of particles in biomedicine. The attention towards the use of synthetic polymers as biomaterials is justified by the fact that they are not affected by limitations in terms of synthesis and processing, as can be the case for natural ones. Moreover, they give the possibility to fabricate new systems with controlled and tailored detailed structures. In vivo studies on PVA MBs presented in this manuscript were guided by in vitro tests that showed good biocompatibility in different cell lines [35, 36] .
The aim of this paper is to understand the biological impact of the injectable PVA MBs in vivo, studying the biodistribution/bioelimination in a mouse model; these issues are pivotal and not predictable as they depend on several variables such as the route of injection, the size, shape and dosing of the administered system, and at last, but not least, the specific PVA texture (i.e., type and amount of chemical crosslinks as well as of physical entanglements networking PVA chains building up the shell structure).
The study of the PVA MBs fate was followed from short to long term in the entire 
Materials and methods

Synthesis of DyLight755-MBs
PVA MBs were synthesised as reported elsewhere [9] . Briefly, 4 g of PVA (numberaverage molecular weight of 30,000 AE 5,000 g/mol and weight-average molecular weight of 70,000 AE 10,000 g/mol, Sigma-Aldrich, Milan, Italy) were dissolved in Floating MBs were separated from solid debris in separatory funnels and several washings were carried out until no debris were observed. The concentration of the obtained MBs was determined by using a cell counting chamber slide for microscopy (Neubauer Chamber) and it was expressed as number of MBs/mL.
MBs were fluorescently-labelled using the DyLight755 N-hydroxysuccinimide (NHS) ester (ThermoFisher Scientific, Milan, Italy). The dye was dissolved in dimethylformamide (10 mg/mL, Sigma-Aldrich, Milan, Italy) and added to around 4 Â were observed by confocal laser scanning microscopy (CLSM, Nikon Eclipse Ti-E C1, Japan). For all experiments a volume of 100 mL of MB suspension (10 8 MBs/mL), both labelled and unlabelled MBs, or of free DyL (2 mg/mL), was administered to mice using three mice per group. For biodistribution and elimination studies mice were injected IV via the retro-orbital plexus under general anaesthesia, whereas for the study concerning the macrophage interaction with MBs, mice were injected intraperitoneally. When necessary, mice were anaesthetised with an intraperitoneal injection of ketamine (Ketaset, 100 mL/kg, MSD Animal Health, Milan, Italy) and xylazine (Rompun, 15 mL/kg, Bayer, Milan, Italy).
Animal model
Blood collection was performed by retro-orbital sinus puncture under general anaesthesia.
After the injection, gross visual observations were made daily for general condition (appearance, demeanour, appetite, hydration, body weight and food consumption).
Euthanasia of anaesthetised mice employed throughout the different experimental procedures was carried out by cervical dislocation as recommended by Legislative Decree no. 26/2014, annex IV.
Haematology and clinical biochemistry
For determination of haematological parameters, 20 mL of whole blood were collected in K2 EDTA microtainers (Becton Dickinson, Milan, Italy) and the samples were analysed using the commercially available automated cell counter 
In vivo and ex vivo fluorescence imaging
A Kodak FX image station 4000 mm was used for in vivo and ex vivo image acquisition of mice injected with a volume of 100 mL of DyL-MB suspension (10 8 MBs/ mL) or the free dye (2 mg/mL).
The loading of the dye per PVA MB was estimated by comparing the signal emission of different amount of free dye with that emitted by a known number of labelled PVA-MBs.
Before treatment with MBs, all mice were anaesthetised. At different time points, they were positioned ventrally or dorsally on the stage of the image station and non-invasively imaged by combining X-rays and fluorescence in the NIR region (excitation filter: 720 AE 10 nm; emission filter: 790 AE 20 nm).
Mice were sacrificed at 100 minutes, 24 hours and 7 days post-injection. Heart, thymus, liver, spleen, lungs, kidneys and pancreas were collected for the ex vivo analysis. The fluorescence signals were registered and overlaid with the X-ray image. Regions of interest (ROIs) were drawn over the signals, and the sum of the fluorescence intensity of each ROI was measured and divided by the area of all the organs. Fluorescence image quantification was carried out by using the freeware ImageJ package.
Macrophage interaction with MBs
In vitro: murine monocyte/macrophage RAW 264.7 (purchased from Istituto Zooprofilattico della Lombardia e dell'Emilia Romagna, Italy) were maintained in culture at 37 C in a 5% CO 2 atmosphere. Cells were cultured in Dulbecco's modified eagle medium (DMEM) with low glucose (1,000 mg/L) supplemented with 10,000 U/mL penicillin-streptomycin, 1% L-glutamine and 10% v/v of heat-inactivated foetal bovine serum (Sigma-Aldrich, Milan, Italy). In vivo: PVA MBs (100 mL of 10 8 MBs/mL) were injected intraperitoneally into CD1 mice. After 1.5 hours, mice were sacrificed; phosphate buffered saline (PBS, 5 mL) at 4 C was injected into the peritoneum followed by gentle massage to promote the detachment of macrophages. A small incision was made in the ventral abdomen to withdraw macrophages suspended in PBS. After one washing in PBS, the sample was fixed and stored in 10% formalin and observed by microscopy (Nikon Inverted Microscope Eclipse Ti-E optical microscopy and scanning electron microscopy).
Scanning electron microscopy (SEM) analysis
The sample described above was post-fixed in 2% osmium tetroxide. After washing with 0.1 M PBS, the sample was dehydrated by a series of incubations in 30%, 50%
and 70% (v/v) ethanol. Dehydration was continued by incubation steps in 95% (v/v) ethanol, absolute ethanol and acetone. Critical-point drying (Agar Scientific, Elektron Technology, UK) with supercritical CO 2 was then performed to prevent cell deformation. Surfaces of the scaffolds were coated with gold and scanned using SEM LEO 1450VP (Carl Zeiss Meditec, Germany) [37] .
Transmission electron microscopy(TEM) and energy dispersive x-ray (EDX) microanalysis
After injection with unlabelled PVA MBs, mice were sacrificed at 10 minutes and 30 days post-injection after collection of blood. Organs (liver, lungs, kidney) were collected and fixed at 4 C in 10% buffered formalin for 24 hours and post-fixed in 2% osmium tetroxide. Tissues were embedded in paraffin and sectioned. After washing with 0.1 M PBS, each sample was dehydrated by a series of incubations in 30%, 50%, 70%, 95% ethanol. Dehydration was continued by incubations in absolute ethanol and propylene oxide. For ultrastructural analysis, the sample was then embedded in Epon resin [38] (Agar Scientific, Elektron Technology, UK). After inclusion, the tissue was cut and stained with heavy metals solutions (uranium acetate and lead citrate) as described by Reynolds [39] . All samples were examined by a Hitachi H-7100 FA transmission electron microscope (Hitachi, Schaumburg, IL, USA). For EDX microanalysis, unstained ultra-thin sections of approximately 100 nm-thick were mounted on copper grids for microanalysis. EDX spectra of microcalcifications were acquired with a Hitachi 7100FA transmission electron microscope (Hitachi, Schaumburg, IL, USA) and an EDX detector (Thermo Scientific, Waltham, MA, USA) at an acceleration voltage of 75 keV and magnification of 12,000. Spectra were semi-quantitatively analysed by the Noram System Six software (Thermo Scientific, Waltham, MA, USA) using the standard-less Cliff-Lorimer k-factor method [40, 41] . The EDX microanalysis apparatus was calibrated using an x-ray microanalysis standard (Micro-Analysis Consultants, UK).
Statistical analysis
All results shown represent the means AE standard error of the mean (SEM) from triplicate experiments performed in a parallel manner. Statistical analyses were performed using a paired t-test. All comparisons were made relative to untreated controls and significance of difference is indicated as *p < 0.05.
Results
The fate of PVA MBs IV injected into mice was analysed over the time. MBs were labelled with the DyLight755, a fluorophore emitting at 776 nm, coupling the NHS ester of the dye with the hydroxyl groups of the PVA MB surface (Fig. 1A) . The successful labelling of the PVA MBs was monitored by CLSM (Fig. 1B) and a quantitative estimation of 10 10 DyL molecules per MB was estimated by comparing the emitted signal of the free dye with the labelled MBs, as registered by the Kodak FX image station 4000 (Fig. 1C) .
The biodistribution of the DyL-MBs in mice was assessed and compared to the free NIR dye, DyL (Fig. 2) . The fluorescent pattern was tracked every 10 minutes for the first 60 minutes, then the permanence of the signal was evaluated for longer timeframes, i.e. 24 hours and 7 days, to identify possible elimination processes. The pharmacokinetics of the free dye alone (Fig. 2b) was quicker than that one of the dye conjugated to MBs (Fig. 2a) . Moreover the free dye accumulated only in the bladder, indicating its excretion was mainly via urine. These two evidences, taken together, allow to discriminate the fluorescence contribution due to a possible detachment of the dye from that one coming from the MBs. In contrast to the free dye, when mice were IV injected with DyL-MBs most of the fluorescent signal was detected in the mid-abdominal region. Starting from the first observation (20 minutes) the signal increased over the time, indicating the progressive and massive accumulation of DyL-MBs in the liver (Fig. 2a) , whereas it was necessary to wait 40 minutes to have a slight fluorescent spot in the bladder.
As expected, using excitation wavelengths in the NIR window, autofluorescence was not detected in mice treated with saline ( Fig. 2c) [42] .
The ex vivo analysis permitted more precise localisation of fluorescence signal and its quantitative estimation at single organ level. The measurements were carried out at 100 minutes, 24 hours and 7 days post-injection and they resulted in an increased detection in the number of the organs involved in the accumulation of the samples with respect to the in vivo evaluation (Fig. 3 ). An intense fluorescence signal was detected at 100 minutes post-injection in the heart, kidneys, lungs, spleen and liver of the mice treated with DyL-MBs and in the kidneys and spleen of the mice injected with the free dye DyL. At later time points a decrease in the fluorescence signal indicated a progressive clearance of the samples that still remained in the reticuloendothelial system organs, i.e. the spleen and the liver (Fig. 3) . In particular, only the DyL-MBs but not the free dye DyL distributed in the spleen, anyway their net fluorescence intensity dropped over the time reaching values around five-fold lower than the initial ones (Fig. 4A) . The liver was able to completely eliminate the free DyL in the time frame from 24 hours to 7 days after administration, while a net fluorescence increase of the DyL-MBs was observed in the liver 24 hours post-administration. After 7 days the fluorescence intensity decreased although it was still detectable (Fig. 4B) . The persistence of PVA MBs in the reticuloendothelial system organs suggests a possible involvement of the macrophages. The ability of macrophages to recognise and phagocytose PVA MBs was investigated both in vitro and in vivo. The in vitro study was carried out by incubating murine monocyte/macrophages RAW264.7
with MBs following the phagocytosis events by time-lapse experiment ( Fig. 5 ), sustaining previous studies [43] .
For the in vivo study, MBs were injected intraperitoneally into mice. SEM analysis of the isolated resident peritoneal macrophages showed clearly the cell plasma membrane approaching the MB surface suggesting an initial step of the internalisation process (Fig. 6 , only part of the macrophage is highlighted).
The observation of MBs in the liver after 7 days from administration prompted us to extend the study to one month. The long-term experiment was justified by Over the course of the experiment, the general health condition of the mice was monitored in terms of changes in gait, posture and behaviour, and during this period, the mice appeared healthy with no differences in growth compared to control animals (Fig. 7A) . At the end of the observations, mice were sacrificed and the organs of PVA MB-injected mice were weighed and compared with the weight of salineinjected ones, with no significant differences found (Fig. 7B) . Haematology (Table 1 ) and biochemistry parameters (data not shown) confirmed the absence of clinically relevant alterations. However, the possible small variations in the number of blood white cells can be justified by the sensitivity of this parameter to the bacterial infections and housing conditions.
The ultrastructural analysis of lungs and kidneys confirmed the good biocompatibility of the MBs: after 10 minutes and 1 month post-injection no significant tissue alterations were identified.
In particular, as far as kidneys were concerned, after 10 minutes only limited ultrastructural alterations were observed in the glomerular areas ( Fig. 8A ) with a complete recovery after one month (Fig. 8B) . Also for lungs the slight thickening of the alveolar septum, observed after 10 minutes post-injection (Fig. 9A) , was fully recovered after one month (Fig. 9B ).
The bioelimination ability of the liver after one month post-injection was tested. To this aim, 10 slices of the liver were analysed and the results at 10 minutes postinjection were compared to samples collected after 1 month. TEM micrographs of samples collected 10 minutes post-MB injection clearly showed the presence in the liver of structures ( (Fig. 10A) . After one month from the injection (Fig. 10B ), MBs were absent in the liver: such finding can be directly caused by the occurrence of an elimination mechanism of PVA MBs. This behaviour is supported by a study on PVA MBs where macrophage phagocytosis is reported as the main mechanism responsible for their elimination [44] .
Discussion
PVA MBs are IV injectable polymeric UCAs. As for all exogenous particles [45] , once exposed to human plasma PVA MBs are covered by an external coating layer of protein usually termed "protein corona". These proteins including serum albumin, serotransferrins and a type of lipoproteins called dysopsonins, are found in the blood and favourably influence the MB biocompatibility. Other binding proteins of PVA MBs include opsonins, immunoglobulin G and complement C3 [46] . They promote events of phagocytosis that participate in the clearance of the exogenous substance from the bloodstream by the monocyte phagocytic system (MPS). However, it is important that the process of clearance is not too rapid so as to prevent UCAs from exerting their function.
The present work aims to determine the biological behaviour of PVA-based MBs once injected into the body. The well-known biocompatibility and "bioinertness"
features of PVA have already permitted the use of this polymer for several applications in food and biomedical fields [47] . However, a construct based on a biocompatible material does not necessarily behave as biocompatible. Many issues must be considered such as size, shape and biointerface as well as chemical and physical modifications occurring during the fabrication of the construct. The absence of PVA MBs cytotoxicity in vitro was previously assessed [35, 36] . This is the first study examining their in vivo biological distribution and bioelimination pathways. It should be pointed out that in a previous study on the MB biodistribution a phagocytic process sustained almost exclusively by the macrophages from lung and liver was highlighted by Barrefelt et al [48] . However, the surface and biointerface of such MBs were deeply different from the ones studied here, where the PVA shell is directly involved in all biointerface processes. As far as the MBs investigated in that study are concerned, the PVA surface was buried by a layer-by-layer process with the outermost layer composed of the negativelycharged sodium poly (styrene sulphonate) (PSS). On the contrary, the surface of the PVA MBs described in this work is neutral and the PVA is the unique material exposed to metabolites and tissues. It is well-known that the surface charge of the particle is one of the most important properties influencing both protein corona effect [49] and cell uptake by macrophages [50] .
Moreover, it has been reported that the layer-by-layer MBs cause renal degeneration 4 hours after injection in mice [48] while the PVA MBs injected mice reported here were in good condition even after one month post-treatment.
The high tolerability of MBs was confirmed by the good general condition and by the absence of alterations in clinical parameters in injected mice. The IV administered MBs accumulated mostly in the liver and much less in the spleen, where the fluorescence signal decreased during the first 7 days of observation. Limited ultrastructural alterations, if any, were monitored in the kidneys, lungs, and liver 10 minutes post-injection, but they fully recovered after 1 month. The MBs were visualised in the hepatic phagocytic cells of the liver, i.e. the Kupffer cells after 10 minutes, nevertheless the clearance was not too fast since after 100 minutes from injection PVA MBs signal was present in most of the organs analysed. Due to their micron-size, MBs are not able to overcome the lining of the endothelium but they can be accessible to Kupffer cells since they are directly exposed to the bloodstream. The ability of phagocytic cells to engulf MBs has been assessed and confirmed both in vitro and in vivo. The hypothesised mechanism of PVA MBs bioelimination is ascribable to macrophages that have a known ability to produce reactive oxygen species that could lead to the oxidation and degradation of PVA polymer [51] and of the crosslinking points connecting the PVA chains in the network of the MBs shell. Alternatively MBs could be directly eliminated without degradation by the liver [17] .
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